Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

• Main Authors: Susanne Wingert (Author), Uwe Reusch (Author), Stefan Knackmuss (Author), Michael Kluge (Author), Michael Damrat (Author), Jens Pahl (Author), Ute Schniegler-Mattox (Author), Thomas Mueller (Author), Ivica Fucek (Author), Kristina Ellwanger (Author), Michael Tesar (Author), Torsten Haneke (Author), Joachim Koch (Author), Martin Treder (Author), Wolfgang Fischer (Author), Erich Rajkovic (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these therapies, which include a narrow therapeutic window mainl...